Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 92

Sort by

Sort Order Select

Journal Articles

Pomalidomide, Dexamethasone, and Daratumumab after Lenalidomide Treatment in Relapsed Refractory Multiple Myeloma: Updated Results from an Open-Label, Multicenter, Phase 2 Trial

David S. Siegel, MD PhD, Gary J. Schiller, MD, Christy J. Samaras, DO, Michael Sebag, MD PhD FRCPC, Jesus G. Berdeja, MD, Siddhartha Ganguly, MD, Jeffrey V. Matous, MD, Kevin W Song, MD FRCPC, Christopher S. Seet, MD PhD, Mirelis Acosta-Rivera, Michael Bar, Donald P. Quick, MD, Bertrand M. Anz, III, MD, Gustavo A. Fonseca, MD, Donna E. Reece, MD, Kim Lee, Weiyuan Chung, Amit Agarwal, MD PhD, Nizar J. Bahlis, MD

Blood (2020) 136 (Supplement 1): 16–17.

https://doi.org/10.1182/blood-2020-134189

Published: 2020

Journal Articles

Carfilzomib, Dexamethasone, and Daratumumab Versus Carfilzomib and Dexamethasone in Relapsed or Refractory Multiple Myeloma: Updated Efficacy and Safety Results of the Phase 3 Candor Study

Meletios A Dimopoulos, Hang Quach, MDFRACP,FRCPA,MBBS, María-Victoria Mateos, Ola Landgren, MD PhD, Xavier Leleu, MD, David S. Siegel, MD PhD, Katja Weisel, MD, Maria Gavriatopoulou, Albert Oriol, MD, Neil K Rabin, Ajay Nooka, MDMPH, Ming Qi, MD PhD, Bifeng Ding, Anita Zahlten-Kumeli, Saad Z. Usmani, MDMBBS,MBA

Blood (2020) 136 (Supplement 1): 26–27.

https://doi.org/10.1182/blood-2020-137602

Published: 2020

Journal Articles

Efficacy and Safety of Idecabtagene Vicleucel (ide-cel, bb2121) in Elderly Patients with Relapsed and Refractory Multiple Myeloma: KarMMa Subgroup Analysis

Jesus G. Berdeja, MD, Noopur S. Raje, MD, David S. Siegel, MD PhD, Yi Lin, MD PhD, Larry D. Anderson, Jr., MD PhD, Paula Rodriguez-Otero, MD PhD, Salomon Manier, MD PhD, Hermann Einsele, MD, Michele Cavo, Anna Truppel-Hartmann, MD, Everton Rowe, PhD, Jill Sanford, MS, Julie Wang, PharmD, PhD, Timothy B. Campbell, MD PhD, Sundar Jagannath, MD

Blood (2020) 136 (Supplement 1): 16–17.

https://doi.org/10.1182/blood-2020-134322

Published: 2020

Journal Articles

A Phase I Study of FT538, a First-of-Kind, Off-the-Shelf, Multiplexed Engineered, iPSC-Derived NK Cell Therapy As Monotherapy in Relapsed/Refractory Acute Myelogenous Leukemia and in Combination with Daratumumab or Elotuzumab in Relapsed/Refractory Multiple Myeloma

Murali Janakiram, MD, Ravi Vij, MBBS, David S. Siegel, MD PhD, Ted Shih, PharmD, Sara Weymer, Bahram Valamehr, PhD, Yu-Waye Chu, MD, Jeffrey S. Miller, MD

Blood (2020) 136 (Supplement 1): 3.

https://doi.org/10.1182/blood-2020-137715

Published: 2020

Journal Articles

Assessment of Minimal Residual Disease in a Phase 1b Study of Once-Weekly Carfilzomib Combined with Lenalidomide and Dexamethasone in Patients with Multiple Myeloma

Ola Landgren, MD PhD, Melissa Alsina, MD, Noa Biran, MD, David H. Vesole, MD PhD, Paul K. Wallace, MS, PhD, Belle Fang, Gregory Arnold, Amy Kimball, MD PhD, David S. Siegel, MD PhD

Blood (2020) 136 (Supplement 1): 28.

https://doi.org/10.1182/blood-2020-133803

Published: 2020

Journal Articles

Higher Incidence of Germline Mutations in DNA Damage Response Genes in Lymphoid Than in Myeloid Neoplasms without Significant Increase in the Prevalence of Clonal Hematopoiesis

Maher Albitar, Michele L. Donato, MD, David S. Siegel, MD PhD, Tatyana A. Feldman, MD, Noa Biran, MD, James K. McCloskey, MD, Jamie L. Koprivnikar, MD, Andrew Ip, MDMSc, Andre H. Goy, MD

Blood (2020) 136 (Supplement 1): 4–5.

https://doi.org/10.1182/blood-2020-140049

Published: 2020

Journal Articles

Idecabtagene Vicleucel (ide-cel, bb2121) in Relapsed and Refractory Multiple Myeloma: Analyses of High-Risk Subgroups in the KarMMa Study

Noopur S. Raje, MD, David S. Siegel, MD PhD, Sundar Jagannath, MD, Sagar Lonial, MD FACP, Nikhil C. Munshi, MD, Philippe Moreau, MD, Hartmut Goldschmidt, MD, Michele Cavo, Anna Truppel-Hartmann, MD, Everton Rowe, PhD, Liping Huang, PhD, Amit Agarwal, MD PhD, Julie Wang, PharmD, PhD, Timothy B. Campbell, MD PhD, Jesus F. San-Miguel, MD PhD, Donna E. Reece, MD

Blood (2020) 136 (Supplement 1): 37–38.

https://doi.org/10.1182/blood-2020-134319

Published: 2020

Journal Articles

First Results of Iberdomide (IBER; CC-220) in Combination with Dexamethasone (DEX) and Daratumumab (DARA) or Bortezomib (BORT) in Patients with Relapsed/Refractory Multiple Myeloma (RRMM)

Blood (2020) 136 (Supplement 1): 16–17.

https://doi.org/10.1182/blood-2020-137743

Published: 2020

Journal Articles

Updated Results from the Phase I CRB-402 Study of Anti-Bcma CAR-T Cell Therapy bb21217 in Patients with Relapsed and Refractory Multiple Myeloma: Correlation of Expansion and Duration of Response with T Cell Phenotypes

Blood (2020) 136 (Supplement 1): 25–26.

https://doi.org/10.1182/blood-2020-140410

Published: 2020

Journal Articles

Idecabtagene Vicleucel (ide-cel, bb2121), a BCMA-Directed CAR T Cell Therapy, in Patients with Relapsed and Refractory Multiple Myeloma: Updated Results from Phase 1 CRB-401 Study

Yi Lin, MD PhD, Noopur S. Raje, MD, Jesus G. Berdeja, MD, David S. Siegel, MD PhD, Sundar Jagannath, MD, Deepu Madduri, MD, Michaela Liedtke, MD, Jacalyn Rosenblatt, MD, Marcela V. Maus, MD PhD, Monica Massaro, MPH, Fabio Petrocca, MD, Andrea Caia, MS, Zhihong Yang, PhD, Timothy B. Campbell, MD PhD, Kristen Hege, MD, Nikhil C. Munshi, MD, James N. Kochenderfer, MD

Blood (2020) 136 (Supplement 1): 26–27.

https://doi.org/10.1182/blood-2020-134324

Published: 2020

Journal Articles

Carfilzomib Cardiovascular Disease: Use of the Atherosclerotic Cardiovascular Disease Score to Predict Cardiovascular Events in Multiple Myeloma Patients Treated with Carfilzomib

Ricardo Parrondo, MD, Tracy Andrews, MSc, Rima M Panchal, MD, Sejal Kothadia, MD, Camille Johnson, MD, Jieqi Liu, Giselle Alexandra Suero-Abreu, MD PhD, David H. Vesole, MD PhD, David S Siegel, MD PhD, Noa Biran, MD

Blood (2018) 132 (Supplement 1): 3254.

https://doi.org/10.1182/blood-2018-99-113722

Published: 2018

Journal Articles

Influence of the Gut Microbiome on Clinical Outcomes in the CPIT-001 Trial, a Phase Ib-IIA Study of Combined Checkpoint Inhibition with Nivolumab and Ipilimumab after Autologous Hematopoietic Stem Cell Transplantation in Patients at High-Risk for Post-Transplant Recurrence

Rena Feinman, PhD, Tracy Andrews, MSc, Iriana Colorado, MSc, Joshua Zenreich, Suzanne Kosky, BS, Themba Nyirenda, PhD, Noa Biran, MD, David S Siegel, MD PhD, David H. Vesole, MD PhD, Michele L. Donato, MD, Scott D. Rowley, MD, Pashna N. Munshi, MD, Michael B Atkins, MD, Tatyana A. Feldman, MD, Lori A. Leslie, MD, Andre Goy, MD, Robert Korngold, PhD, Alan P Skarbnik, MD, Andrew L. Pecora, MD

Blood (2018) 132 (Supplement 1): 3443.

https://doi.org/10.1182/blood-2018-99-117669

Published: 2018

Journal Articles

Pomalidomide + Low-Dose Dexamethasone + Daratumumab in Relapsed and/or Refractory Multiple Myeloma after Lenalidomide-Based Treatment Failure

Blood (2018) 132 (Supplement 1): 3271.

https://doi.org/10.1182/blood-2018-99-111920

Published: 2018

Journal Articles

Efficacy and Safety of Carfilzomib and Dexamethasone in Lenalidomide Exposed and Refractory Multiple Myeloma Patients: Combined Analysis of Carfilzomib Trials

Maria-Victoria Mateos, MD PhD, Jesus G. Berdeja, MD, Meletios A Dimopoulos, MD, David S Siegel, MD PhD, P Joy Ho, MBBS(Syd) DPhil(Oxon) FRACP FRCPA FFSc(RCPA), Mei Huang, Martina Sersch, Anita Zahlten-Kumeli, Amy S Kimball, Katja Weisel, MD

Blood (2018) 132 (Supplement 1): 1963.

https://doi.org/10.1182/blood-2018-99-112600

Published: 2018

Journal Articles

Immune Profiling of Relapsed or Refractory Multiple Myeloma Patients Treated with Pomalidomide and Low-Dose Dexamethasone in Combination with Daratumumab

Blood (2018) 132 (Supplement 1): 2012.

https://doi.org/10.1182/blood-2018-99-111554

Published: 2018

Journal Articles

Phase I/II Study of Escalating Doses of Thalidomide in Conjunction with Bortezomib and High Dose Melphalan As a Conditioning Regimen for Autologous Stem Cell Transplantation in Patients with Multiple Myeloma

Noa Biran, MD, Shijia Zhang, MD PhD, Scott D. Rowley, MD, David H. Vesole, MD PhD, Michele L. Donato, MD, Alan P Skarbnik, MD, Joshua R Richter, MD, Andrew L. Pecora, MD, David S Siegel, MD PhD

Blood (2018) 132 (Supplement 1): 2154.

https://doi.org/10.1182/blood-2018-99-114832

Published: 2018

Journal Articles

Patient Treatment Preferences for Relapsed/Refractory Multiple Myeloma: Are Patients Willing to Trade Off Efficacy for Tolerability?

Daniel Auclair, PhD, Carol Mansfield, PhD, Ajai Chari, MD, Craig E. Cole, MD, Mark A. Fiala, BS, Jonathan L Kaufman, MD, Gregory Orloff, MD, David S Siegel, MD PhD, Jeffrey A Zonder, MD, Brennan Mange, Jennifer Yesil, MS, Mehul Dalal, PhD, Joseph Mikhael, MD FRCPC, MD

Blood (2018) 132 (Supplement 1): 614.

https://doi.org/10.1182/blood-2018-99-113087

Published: 2018

Journal Articles

Carfilzomib-Lenalidomide-Dexamethasone Versus Bortezomib-Lenalidomide-Dexamethasone in Patients with Newly Diagnosed Multiple Myeloma: Results from the Prospective, Longitudinal, Observational Commpass Study

Ola Landgren, MD PhD, David S Siegel, MD PhD, Daniel Auclair, PhD, Ajai Chari, MD, Michael Boedigheimer, Tim Welliver, MD PhD, Khalid Mezzi, Karim Iskander, Andrzej Jakubowiak, MD PhD

Blood (2018) 132 (Supplement 1): 799.

https://doi.org/10.1182/blood-2018-99-112289

Published: 2018

Journal Articles

Comparison of Peripheral Blood Stem Cell Mobilization for Multiple Myeloma Patients over 70 Years of Age with Younger Patients

Ning Dong, MD, David S Siegel, MD PhD, Phyllis McKiernan, Noa Biran, MD, Alan P Skarbnik, MD, David H. Vesole, MD PhD, Andrew L. Pecora, MD, Scott D. Rowley, MD, Michele L. Donato, MD

Blood (2018) 132 (Supplement 1): 4554.

https://doi.org/10.1182/blood-2018-99-117498

Published: 2018

Journal Articles

Safety and Efficacy Data for Combined Checkpoint Inhibition with Ipilimumab (Ipi) and Nivolumab (Nivo) As Consolidation Following Autologous Stem Cell Transplantation (ASCT) for High-Risk Hematological Malignancies — CPIT-001 Trial

Alan P Skarbnik, MD, Michele L. Donato, MD, Robert Korngold, PhD, Rena Feinman, PhD, Scott D. Rowley, MD, Andre Goy, MD, David H. Vesole, MD PhD, Pashna N. Munshi, MD, David S Siegel, MD PhD, Tatyana A. Feldman, MD, Noa Biran, MD, Lori A. Leslie, MD, Michael B Atkins, MD, Andrew L. Pecora, MD

Blood (2018) 132 (Supplement 1): 256.

https://doi.org/10.1182/blood-2018-99-113586

Published: 2018

NARROW

Pomalidomide, Dexamethasone, and Daratumumab after Lenalidomide Treatment in Relapsed Refractory Multiple Myeloma: Updated Results from an Open-Label, Multicenter, Phase 2 Trial

Carfilzomib, Dexamethasone, and Daratumumab Versus Carfilzomib and Dexamethasone in Relapsed or Refractory Multiple Myeloma: Updated Efficacy and Safety Results of the Phase 3 Candor Study

Efficacy and Safety of Idecabtagene Vicleucel (ide-cel, bb2121) in Elderly Patients with Relapsed and Refractory Multiple Myeloma: KarMMa Subgroup Analysis

A Phase I Study of FT538, a First-of-Kind, Off-the-Shelf, Multiplexed Engineered, iPSC-Derived NK Cell Therapy As Monotherapy in Relapsed/Refractory Acute Myelogenous Leukemia and in Combination with Daratumumab or Elotuzumab in Relapsed/Refractory Multiple Myeloma

Assessment of Minimal Residual Disease in a Phase 1b Study of Once-Weekly Carfilzomib Combined with Lenalidomide and Dexamethasone in Patients with Multiple Myeloma

Higher Incidence of Germline Mutations in DNA Damage Response Genes in Lymphoid Than in Myeloid Neoplasms without Significant Increase in the Prevalence of Clonal Hematopoiesis

Idecabtagene Vicleucel (ide-cel, bb2121) in Relapsed and Refractory Multiple Myeloma: Analyses of High-Risk Subgroups in the KarMMa Study

First Results of Iberdomide (IBER; CC-220) in Combination with Dexamethasone (DEX) and Daratumumab (DARA) or Bortezomib (BORT) in Patients with Relapsed/Refractory Multiple Myeloma (RRMM)

Updated Results from the Phase I CRB-402 Study of Anti-Bcma CAR-T Cell Therapy bb21217 in Patients with Relapsed and Refractory Multiple Myeloma: Correlation of Expansion and Duration of Response with T Cell Phenotypes

Idecabtagene Vicleucel (ide-cel, bb2121), a BCMA-Directed CAR T Cell Therapy, in Patients with Relapsed and Refractory Multiple Myeloma: Updated Results from Phase 1 CRB-401 Study

Carfilzomib Cardiovascular Disease: Use of the Atherosclerotic Cardiovascular Disease Score to Predict Cardiovascular Events in Multiple Myeloma Patients Treated with Carfilzomib

Influence of the Gut Microbiome on Clinical Outcomes in the CPIT-001 Trial, a Phase Ib-IIA Study of Combined Checkpoint Inhibition with Nivolumab and Ipilimumab after Autologous Hematopoietic Stem Cell Transplantation in Patients at High-Risk for Post-Transplant Recurrence

Pomalidomide + Low-Dose Dexamethasone + Daratumumab in Relapsed and/or Refractory Multiple Myeloma after Lenalidomide-Based Treatment Failure

Efficacy and Safety of Carfilzomib and Dexamethasone in Lenalidomide Exposed and Refractory Multiple Myeloma Patients: Combined Analysis of Carfilzomib Trials

Immune Profiling of Relapsed or Refractory Multiple Myeloma Patients Treated with Pomalidomide and Low-Dose Dexamethasone in Combination with Daratumumab

Phase I/II Study of Escalating Doses of Thalidomide in Conjunction with Bortezomib and High Dose Melphalan As a Conditioning Regimen for Autologous Stem Cell Transplantation in Patients with Multiple Myeloma

Patient Treatment Preferences for Relapsed/Refractory Multiple Myeloma: Are Patients Willing to Trade Off Efficacy for Tolerability?

Carfilzomib-Lenalidomide-Dexamethasone Versus Bortezomib-Lenalidomide-Dexamethasone in Patients with Newly Diagnosed Multiple Myeloma: Results from the Prospective, Longitudinal, Observational Commpass Study

Comparison of Peripheral Blood Stem Cell Mobilization for Multiple Myeloma Patients over 70 Years of Age with Younger Patients

Safety and Efficacy Data for Combined Checkpoint Inhibition with Ipilimumab (Ipi) and Nivolumab (Nivo) As Consolidation Following Autologous Stem Cell Transplantation (ASCT) for High-Risk Hematological Malignancies — CPIT-001 Trial

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only